Nonnenmacher A, Hopp H, Dudenhausen J
Klinik für Geburtsmedizin, Charité-Universitätsmedizin Berlin.
Z Geburtshilfe Neonatol. 2009 Oct;213(5):201-6. doi: 10.1055/s-0029-1225640. Epub 2009 Oct 23.
The aim of this study was to compare the efficacy and side effects of atosiban with those of fenoterol (pulsatile administration) for acute tocolysis.
A prospective, open-label, randomised controlled trial was performed. Patients in preterm labour at 24+0 to 33+6 weeks of gestation were randomised to receive atosiban (A) or fenoterol (F) pulsatile administration. Primary outcome was the arrest of preterm labour.
The proportion of woman remaining undelivered at 48 hours (86.3% atosiban group and 79.6% fenoterol group) and at 7 days (78.4% vs. 66.7%) was comparable. The incidence of maternal cardiovascular side effects was lower in the atosiban group (4% vs. 78%, p=0.0). Tocolysis was terminated as a result of maternal adverse effects in the fenoterol group (9%). Fetal tachycardia was lower in the atosiban group (2% vs. 22%). The mean duration of tocolytic administration was lower in the atosiban group (19 h vs. 24.5 h, p<0.05).
The adverse effects in the pulsatile administration of fenoterol for short duration were only dependent on the initial dosage for the arrest of preterm labour. Neonatal outcome were similar between the treatment groups and were rather related to the gestational age not to the tocolytic agent.
Atosiban was comparable in clinical effectiveness and was associated with fewer maternal and fetal adverse effects, so that fenoterol cannot be recommended. Completion of tocolytic therapy 12 hours after arrest of preterm labour is effective and associated with a short mean duration.
本研究旨在比较阿托西班与非诺特罗(脉冲给药)用于急性宫缩抑制的疗效及副作用。
进行了一项前瞻性、开放标签、随机对照试验。妊娠24 + 0至33 + 6周的早产患者被随机分配接受阿托西班(A)或非诺特罗(F)脉冲给药。主要结局是早产停止。
48小时时未分娩的女性比例(阿托西班组为86.3%,非诺特罗组为79.6%)以及7天时(78.4%对66.7%)具有可比性。阿托西班组产妇心血管副作用的发生率较低(4%对78%,p = 0.0)。非诺特罗组因产妇不良反应而终止宫缩抑制治疗的比例为9%。阿托西班组胎儿心动过速的发生率较低(2%对22%)。阿托西班组宫缩抑制治疗的平均持续时间较短(19小时对24.5小时,p < 0.05)。
短期脉冲给药非诺特罗的不良反应仅取决于早产停止时的初始剂量。各治疗组的新生儿结局相似,且更多与胎龄相关而非宫缩抑制剂。
阿托西班在临床疗效上相当,且产妇和胎儿的不良反应较少,因此不推荐使用非诺特罗。早产停止12小时后完成宫缩抑制治疗是有效的,且平均持续时间较短。